Analytical Strategies for GLP-1 Agonists: Aggregation, Related Substances and Stability Workflows
In this presentation, we will demonstrate HPLC methodologies tailored for a range of GLP-1 agonist therapeutics. Our discussion will include the principles and applications of Size Exclusion Chromatography (SEC) for aggregation analysis, as well as reversed-phase techniques for the characterization of related substances and the development of stability-indicating methods across multiple GLP-1 drug products.
Key Learning Points
- Learn how to apply Size Exclusion Chromatography (SEC) theory and principles to analyze peptide aggregation.
- Identify and evaluate key considerations in developing and optimizing Reversed Phase HPLC methods for the separation of closely related peptide substances.
- Find how to differentiate the outcomes of forced degradation studies in peptide drug products from known related substances.
Who Should Attend
- Any LC users working with, or interested in analyzing peptide therapeutics by HPLC.
Speaker: Speakers: Lucia Geis Asteggiante (Senior Technical Specialist, Phenomenex)
Lucia is a Senior Technical Specialist that has recently joined Phenomenex’s Global Technical Team. She has a broad experience in the field of Analytical Chemistry with a particular focus on LC chromatography coupled with mass spectrometry. Lucia comes from a strong academic and regulatory background with experiences ranging from method development and analysis of small molecules to large protein complexes. She gained her Ph.D. at the University of Maryland - College Park, USA and did her post-doctoral work at the University of Oxford, UK. During her time as a researcher, she has authored/co-authored 23 scientific publications and 2 book chapters.
